Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas; ODM derived from:


Versions (1) ▾
  1. 10/22/19
Copyright Holder:
Uploaded on:

October 22, 2019

No DOI assigned. To request one pleaselog in.
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Cancer NCT01078649

Eligibility Cancer NCT01078649

  1. StudyEvent: Eligibility
    1. Eligibility Cancer NCT01078649
Inclusion Criteria
histologically confirmed solid tumor or lymphoma;
locally advanced or metastatic disease for which no life prolonging therapy is available and no standard therapy is judged appropriate by the investigator;
eastern cooperative oncology group performance status ≤ 1;
adequate hematologic function as indicated by, anc ≥ 1,500/mm3, hgb >9.0 g/dl, platelet count ≥ 100,000/mm3
adequate renal and liver function as indicated by serum creatinine ≤ 1.0 x uln or creatinine clearance of > 60 cc/min, serum albumin ≥ 3.0 gm/dl, total bilirubin < 1.0 x uln, ast and alt ≤ 2.5 x uln ; alkaline phosphatase ≤2.5 x uln
negative hepatitis b and hepatitis c testing;
qtc interval ≤450ms.
Exclusion Criteria
radiation within 14 days of study entry, thoracic radiation within 28 days of study entry. patients who have received prior radiotherapy must have discontinued steroids for 14 days prior to study entry and be clinically stable;
not recovered to ≤ grade 1 toxicity from prior radiotherapy or chemotherapy agents;
use or requirement for use of aspirin or aspirin containing products with >81 mg of aspirin per day;
history of gastrointestinal bleeding within 1 year;
history of diabetes mellitus requiring treatment with oral agents or insulin;
active rheumatoid arthritis, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation;
known or suspected wilson's disease, or other conditions that affect copper accumulation or regulation;
prior treatment with iap inhibitors.